The 6th edition of the International HBV Cure Workshop featured the world's most prominent and distinguished speakers that discussed the most current and trending issues in the field.

Meeting category
Date(s)
6 Nov 2019
Location
Toronto,
Canada
Organizer

International Workshop on HBV Cure 2019
Related Enduring Materials
Enduring Materials
Program
Wednesday, 6 November 2019
- 08:00
08:00 EDT
Welcome
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Session 1: Review of Nucleoside analogue Stopping studies -
Chairs

David Wong
-

Marion Peters, MA
University of California, USA
08:10 EDT
Stopping Nucleos(t)ide Analogues: Clinical outcomes of HBs Loss, retreatment and flares
08:25 EDT
Virological biomarkers in patients stopping Nucs
08:40 EDT
Immunological response after stopping Nucs
Session 2: New Endpoints and Biomarkers -
Chairs

Robert Gish
Robert G. Gish Consultants LLC
09:20 EDT
Review of the FDA/EMA HBV Endpoints Meeting
09:35 EDT
Are HBcrAg, HBV RNA and anti-HBc Viable Biomarkers
09:50 EDT
Are ALT Flares Associated with Improved Virological Clearance
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Session 3: How to make immunology curative -
Chairs

Georg Lauer
-
10:55 EDT
Restoration of B cell Antibody Production in Chronic HBV patients
11:10 EDT
Using FNAB to Investigate Intrahepatic Immunology
11:25 EDT
Springbank RIG-I Agonist (Inarigivir)

Cheleas MacFarlane
Springbank Pharmaceuticals, Inc.
11:35 EDT
Gilead TLR8 agonist (GS-9688)
Session 4: Update on Viral Targets for HBV/HDV Therapy -
Chairs

Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Victorian Infectious Diseases Reference Laboratory

Raymond Schinazi, PhD, DSc
Emory University Center for AIDS Research (CFAR), USA
13:30 EDT
Mechanisms of cccDNA Maintenance and progress on Measurement
13:45 EDT
Capsid inhibitor/cccDNA Inhibitor - Roche
13:55 EDT
Elimination of Residual HBV Replication and Prevention of cccDNA Generation with the Combination of NrtI and Core Inhibitor
14:25 EDT
MyrB + IFN effect on HBV & HDV

Stefan Urban
Heidelberg University Hospital
Session 5: New Drug Combinations and Study Design -
Chairs
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
15:45 EDT
FDA Guidance on New Combinations
16:00 EDT
Hypothesized Synergies in new cobmination treatment beyond nucs
16:15 EDT
Study Design with New Combinations
17:15 EDT
Closure of workshop
Overview
Committees
Support
Endorsers